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ABSTRACT
The RAF/MEK/ERK cascade is a conserved intracellular signaling pathway that 
controls fundamental cellular processes including growth, proliferation, differentiation, 
survival and migration. Aberrant regulation of this signaling pathway has long been 
associated with human cancers. A major point of regulation of this pathway occurs 
at the level of the serine/threonine protein kinase C-RAF. Here, we show how the 
E3 ubiquitin ligase HERC1 regulates ERK signaling. HERC1 knockdown induced 
cellular proliferation, which is associated with an increase in ERK phosphorylation 
and in C-RAF protein levels. We demonstrate that overexpression of wild-type C-RAF 
is sufficient to increase ERK phosphorylation. Experiments with pharmacological 
inhibitors of RAF activity, or with interference RNA, show that the regulation of ERK 
phosphorylation by HERC1 is RAF-dependent. Immunoprecipitation, pull-down and 
confocal fluorescence microscopy experiments demonstrate an interaction between 
HERC1 and C-RAF proteins. Mechanistically, HERC1 controls C-RAF stability by 
regulating its polyubiquitylation in a lysine 48-linked chain. In vitro ubiquitylation 
assays indicate that C-RAF is a substrate of the E3 ubiquitin ligase HERC1. Altogether, 
we show how HERC1 can regulate cell proliferation through the activation of ERK 
signaling by a mechanism that affects C-RAF’s stability.
INTRODUCTION
The RAF/MEK/ERK signaling pathway controls 
many fundamental cellular processes including growth, 
proliferation, differentiation, survival and migration. In 
this conserved intracellular pathway, upon the stimulation 
of receptor tyrosine kinases at the cell surface, a guanine 
nucleotide exchange factor promotes the activation of 
GTPase RAS through the exchange of GDP to GTP. GTP-
bound RAS interacts and activates RAF at the plasma 
membrane. Subsequently, activated RAF phosphorylates 
and activates MEK, which in turn phosphorylates 
and activates ERK. ERK phosphorylates hundreds of 
substrates, which mediate many of the pleiotropic effects 
of this pathway. Dysregulation of this phosphorylation 
cascade has long been associated with human cancers. 
Thus, ERK activation is observed in most human cancers 
and, in about one-third of them, it is driven by mutational 
activation of its pathway components [1–3]
Like protein phosphorylation, protein ubiquitylation 
has also emerged as a prevalent posttranslational 
modification utilized in the regulation of cellular 
processes. It consists of the covalent attachment of a small 
polypeptide ubiquitin to target proteins. This intracellular 
process occurs in a three-step reaction requiring three 
different enzymes: a ubiquitin-activating enzyme (E1), a 
ubiquitin conjugating enzyme (E2), and a ubiquitin ligase 
enzyme (E3). Ubiquitin is first activated by an E1, which 
then promotes the conjugation of ubiquitin onto an E2. 
Finally, ubiquitin is conjugated to a lysine residue of a 
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target protein by an E3, which acts as a specific adaptor 
for the target protein. This cycle of ubiquitin conjugation 
can be repeated in order to build different ubiquitin chains 
with different functions. [4–7].
The HERC family proteins are E3 ubiquitin ligases. 
They contain two characteristic domains: the HECT 
domain, and one or more RCC1-like domains. Proteins 
containing RCC1-like domains function as GTPase 
regulators, whereas proteins with HECT domains function 
as E3 ubiquitin ligases [8]. These two activities are 
essential in many important cellular processes such as cell 
cycle, cell signaling, and membrane trafficking. Mutations 
affecting these domains have been mainly associated with 
cancer, neurological disorders, male fertility, and the 
antiviral response [9, 10]. In humans, six HERC genes 
have been reported which encode two subgroups of 
HERC proteins: large (HERC1-2) and small (HERC3-6). 
The giant HERC1 protein was the first to be identified. 
It is expressed ubiquitously in mammalian tissues, with 
slightly higher levels in brain and testis, and the lowest 
levels in liver. Its subcellular localization is restricted 
to the cytoplasm and Golgi/vesicular-like membrane 
compartments [11]. HERC1 has been implicated in 
membrane trafficking, cell proliferation/growth and 
apoptosis through its interaction with ARF, Rab, Clathrin, 
M2-pyruvate kinase, TSC2 and BAK proteins [11–15]. 
In vivo studies have implicated HERC1 in neurological 
disorders. Evidence was first obtained with the 
tambaleante mutant mouse, which carries a spontaneous 
Gly483Glu mutation in the amino-terminal RCC1-like 
domain of the HERC1 protein and causes an increase of 
mutated protein levels. These animals are smaller, have a 
reduced lifespan, and an ataxic syndrome caused by the 
almost complete loss of cerebellar Purkinje cells during 
adult life [16]. More recent analyses have also identified 
alterations at neuromuscular junctions in these mice, as 
well as in other neurons [17–19]. Biallelic mutations in 
human HERC1 have been associated with overgrowth, 
intellectual disability and some autistic features [20–24]. 
For these reasons, it has been recommended to consider 
HERC1 mutations in the differential diagnosis of severe 
intellectual disability and behavioral problems [23, 24]. 
HERC1 has also been involved in cancer. Mutations in 
HERC1 were detected in leukemias [25–27], breast 
cancers [28, 29] and, more recently, HERC1 has been 
associated with non-melanoma skin cancer through 
regulation of E6-mediated BAK degradation [15].
Despite previous evidence indicating a role of E3 
ubiquitin ligase HERC1 in proliferative processes, there 
is very little information on the molecular mechanisms 
involved, as well as on the ubiquitylation substrates of 
this ligase. In this study, we found that cell proliferation 
was increased by ERK activation in a HERC1-dependent 
manner; HERC1 interacts with C-RAF and regulates 
its stability. Our data show that the E3 ubiquitin ligase 
HERC1 controls the ERK signaling pathway by regulation 
of C-RAF protein levels via ubiquitylation.
RESULTS
HERC1 regulates cell proliferation and ERK 
signaling
Previous work suggests an important role of the E3 
ubiquitin ligase HERC1 in cancer [15, 25–29]. In order 
to study the function of HERC1 in cell proliferation, we 
decided to perform a clonogenic assay in HERC1-depleted 
human cancer cells. Human osteosarcoma U2OS cells, 
frequently used in cell signaling studies, were transfected 
with two different small interfering RNA (siRNA) of 
HERC1 (Q1 or Q4). Non-targeting (NT) siRNA was 
also transfected and used as a negative control. A great 
decrease in HERC1 protein levels was observed by 
Western blot analysis 72 hours after transfection (Figure 
1A). HERC1 depletion had no effect on different loading 
controls such as α-Tubulin and Clathrin Heavy Chain 
(CHC) (Figure 1). Transfected cells were grown for 12-
15 days in a clonogenic assay as indicated in “Materials 
and Methods”. After this time, cells were visualized 
by crystal violet staining (Figure 1B). A significant 
increase in the number of colonies was observed in cells 
transfected with HERC1 siRNA when compared with 
cells transfected with NT siRNA. These observations were 
quantified by an absorbance analysis of the crystal violet 
staining (Figure 1C). To check whether this effect could 
be observed in other cell types, cervical cancer HeLa 
cells were also transfected with the above siRNAs. We 
observed similar effects in this human cell line (Figure 
1D-F) as in U2OS cells (Figure 1A-C). These results 
suggest a regulatory role of HERC1 in cell proliferation.
Since ERK activation is required for cell 
proliferation, the activation of cell proliferation by 
HERC1 knockdown (Figure 1) led us to analyze whether 
ERK signaling was activated under these conditions. 
The analysis of ERK1/2 phosphorylation with phospho-
specific antibodies is frequently used to assess ERK 
activation. We observed a significant increase of ERK1/2 
phosphorylation (p-ERK) in U2OS cells transfected with 
HERC1 siRNA (Figure 2A). The increase in p-ERK 
cannot be due to an augmented level of ERK proteins 
because HERC1 depletion does not modify ERK protein 
levels (Figure 2A). Similar results were observed in HeLa 
cells and in Human embryonic kidney cells 293T (HEK-
293T) (Figure 2B-C). ERK is phosphorylated by the ERK 
kinase MEK. To show that the increase of p-ERK protein 
levels was due to an increase in MEK activity, we used 
a highly selective inhibitor of MEK activity: U0126. 
Treatment with this inhibitor greatly reduced the ability of 
HERC1 siRNA to induce ERK phosphorylation (Figure 
2D). Although we cannot discard that other factors could 
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be involved in the regulation of ERK phosphorylation, 
these data show a regulation of ERK signaling by HERC1.
HERC1 regulates ERK pathway by RAF 
activation
Activation of the ERK signaling pathway occurs 
upon subsequent and sequential activation of RAF, MEK, 
and ERK kinases. We investigated the involvement of 
the first kinase of this signal transduction cascade in the 
activation of ERK by HERC1 knockdown. Since there are 
three isoenzymes in mammals, we analyzed protein levels 
of A-RAF, B-RAF and C-RAF by immunoblotting in 
U2OS cells transfected with siRNA of HERC1. NT siRNA 
was used as a negative control. We observed in conditions 
where HERC1 knockdown activated ERK (p-ERK), that 
Figure 1: HERC1 regulates cell proliferation. Cells were transfected with non-targeting (NT) or HERC1 siRNA. For U2OS cells, 
two different HERC1 siRNAs (Q1 and Q4) were used. (A, D) Seventy-two hours later, lysates were analyzed by immunoblotting with 
antibodies against the indicated proteins. (B, C, E, F) Colony formation assays were performed as indicated in “Materials and Methods”. 
After 12-15 days, cells were stained with crystal violet (B, E). Crystal violet absorbance at 550 nm was quantified (n = 6 for U2OS cells; 
n = 3 for HeLa cells) (C, F). CHC: Clathrin heavy chain. Data are expressed as mean ± S.E.M. Statistical analysis was carried out as 
described under “Materials and Methods”. The differences are shown with respect to NT siRNA. ***, p< 0.001.
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Figure 2: HERC1 regulates ERK signaling. (A) Lysates from U2OS cells transfected with NT or HERC1 siRNAs (Q1 or Q4) were 
analyzed by immunoblotting with antibodies against the indicated proteins. Levels of HERC1 and p-ERK were quantified and normalized 
with respect to CHC and ERK levels, respectively (n = 4). (B-C) Lysates from HeLa or HEK-293T cells were analyzed as above (n = 6 
for HeLa cells; n = 4 for HEK-293T cells). (D) U2OS cells were transfected with NT or HERC1 (Q1) siRNAs. Seventy-two hours later, 
cells were treated with the inhibitor U0126 (10 μM) for 1 hour. Lysates were analyzed as in (A) (n = 3). Data are expressed as mean ± 
S.E.M. Statistical analysis was carried out as described under “Materials and Methods”. The differences are shown with respect to NT 
siRNA. *, p< 0.05; **, p< 0.01; ***, p< 0.001.
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the level of C-RAF protein increased (Figure 3A). In the 
same conditions, A-RAF and B-RAF levels were not 
significantly modified (Figure 3B-C). This result would 
suggest that the increase of C-RAF protein level could be 
responsible for ERK activation by HERC1 knockdown. 
To confirm this point, we repeated these experiments by 
transfecting U2OS cells with C-RAF siRNA. C-RAF 
depletion decreased ERK activation produced by the 
HERC1 knockdown (Figure 4A, compare lanes 5 and 2). 
However, we also observed a remnant level of p-ERK 
slightly higher than in NT siRNA cells (Figure 4A, 
compare lanes 5 and 1). We analyzed A-RAF and B-RAF 
proteins in order to test the possibility of a compensatory 
mechanism being contributed by other RAF isoforms [1, 
30]. We did not observe significant changes in the amount 
of these proteins in the presence of C-RAF siRNA (Figure 
4A, lane 5). We also performed HERC1 knockdown 
experiments with A-RAF siRNA, B-RAF siRNA, and 
with siRNA of the three isoforms. Under these conditions, 
B-RAF depletion decreased ERK activation produced 
by HERC1 knockdown to a similar extent as C-RAF 
siRNA (Figure 4A, lane 4), suggesting the involvement 
of C-RAF/B-RAF heterodimers in this signaling. A-RAF 
depletion only slightly decreased ERK activation produced 
by HERC1 knockdown (Figure 4A, compare lanes 3 and 
2), suggesting that A-RAF contributes less in this type of 
signaling. In agreement with all these data, knockdown of 
the three isoforms did not result in ERK activation (Figure 
4A, lane 6).
To confirm that ERK activation by HERC1 
knockdown was dependent on RAF activity, we used 
two different inhibitors of RAF activity: Sorafenib and 
LY3009120. We observed that the treatment of U2OS 
cells with these inhibitors impaired ERK activation from 
HERC1 knockdown (Figure 4B-C). Interestingly, a small 
increase of p-ERK after HERC1 knockdown was observed 
in the presence of Soranefib (Figure 4B, lane 4), but not 
in the presence of LY3009120 (Figure 4C, lane 4). This 
could be due to the different specificities of these RAF 
inhibitors: Soranefib is a specific inhibitor of B-RAF and 
C-RAF, whereas LY3009120 is a pan-RAF inhibitor that 
inhibits all RAF isoforms.
To conclude that HERC1 knockdown promotes cell 
proliferation (Figure 1) via C-RAF stabilization (Figure 
3) and RAF activation (Figure 4), cell proliferation must 
be reverted by C-RAF inhibition or RAF knockdown. 
We observed in conditions where HERC1 knockdown 
increased the number of colonies, that it was necessary to 
knockdown the three RAF isoforms in order to avoid this 
increase (Figure 5).
Overexpression of C-RAF is enough to activate 
C-RAF and ERK signaling
The increase in C-RAF protein by HERC1 knockdown 
(Figure 3 and 4) indicates that HERC1 could be involved 
in the regulation of C-RAF stability. We confirmed this 
regulation in additional human cancer cells (H1299 
and A549). This regulation was independent of p53 
expression (H1299 cells do not express the p53 protein 
and A549 cells express wild-type p53) (Figure 6A). To 
be sure that this regulation was not restricted to human 
cancer cells, we also demonstrated this increase in C-RAF 
protein amount by HERC1 knockdown in HEK-293T 
cells (Figure 6A). To show that the increase of C-RAF 
is enough to activate ERK, U2OS cells were transfected 
with a plasmid expressing wild-type C-RAF. We observed 
how C-RAF overexpression produced an increase in ERK 
phosphorylation (Figure 6B). These data show that an 
increase of the C-RAF quantity is enough to activate ERK 
signaling.
C-RAF activation requires C-RAF oligomerization 
[1, 31, 32]. To show that C-RAF was active after HERC1 
knockdown, we analyzed C-RAF oligomerization using 
a protein cross-linking assay [33]. U2OS cells were 
transfected with HERC1 or NT siRNA and analyzed 
72 hours later. Cell lysates were isolated, treated with 
increasing amounts of glutaraldehyde, and analyzed 
by SDS-PAGE and immunoblotting with anti-C-
RAF antibodies. As shown in Figure 6C, C-RAF 
oligomerization was increased in HERC1 knockdown 
cells.
HERC1 interacts with C-RAF
To analyze whether HERC1 can interact with 
C-RAF, we performed immunoprecipitation experiments 
in HEK-293T cells with a specific antibody (Bvg6) 
against HERC1. This antibody could coimmunoprecipitate 
endogenous C-RAF with endogenous HERC1 (Figure 
7A). Pre-immune serum (PI) was used as a negative 
control. In agreement with the formation of oligomers 
between RAF proteins [34–36], A-RAF and B-RAF 
isoforms were also present in the coimmunoprecipitate 
(Figure 7A). The interaction between HERC1 and C-RAF 
proteins was more evident in HEK-293T cells transfected 
with C-RAF-GFP (Figure 7B). The interaction between 
endogenous proteins was also confirmed in HeLa cells and 
in rat liver (Figure 7C).
We analyzed whether activation of ERK signaling 
with epidermal growth factor (EGF) could modulate this 
interaction. HEK-293T cells were deprived of serum 
overnight and then stimulated with EGF for 5 min. An 
increase of p-ERK was detected (Figure 7D). Under these 
conditions, we did not observe a significant change in the 
interaction between HERC1 and C-RAF proteins.
To identify the region of HERC1 interacting with 
C-RAF, we expressed a series of GFP-HERC1 fusion 
proteins (Figure 8A) in HEK-293T cells, and performed 
pull-down assays with GFP-binding beads. Constructs 
GFP-HERC1 (1-412), GFP-HERC1 (1-1334) and GFP-
HERC1 (1-2958) could pull-down endogenous C-RAF 
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protein, indicating that amino acid residues 1-412 of 
HERC1 are enough to interact with C-RAF. To map the 
region of C-RAF involved in the interaction with HERC1, 
we transfected HEK-293T cells with plasmids expressing 
myc-HERC1 (amino acid residues 1-1413) and several 
GFP-C-RAF fusion proteins (Figure 8B). Pull-down 
experiments with GFP-binding beads showed that amino 
acid residues 301-648 of C-RAF, which encloses its kinase 
domain, are involved in this interaction. Additionally, 
confocal immunofluorescence analysis showed the 
colocalization of endogenous C-RAF and HERC1 proteins, 
and overexpressed C-RAF-GFP and myc-HERC1 (1-1413) 
proteins (Figure 9). Altogether, these data confirm the 
interaction between HERC1 and C-RAF proteins.
Figure 3: HERC1 regulates C-RAF protein levels. (A-C) Lysates from U2OS cells transfected with NT or HERC1 siRNAs were 
analyzed by immunoblotting with antibodies against the indicated proteins. Levels of RAF proteins were quantified and normalized with 
respect to CHC levels (n = 4). Data are expressed as mean ± S.E.M. Statistical analysis was carried out as described under “Materials and 
Methods”. The differences are shown with respect to NT siRNA. ***, p< 0.001.
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Figure 4: ERK activation is RAF dependent. (A) Lysates from U2OS cells transfected with the indicated siRNA (NT: non-targeting, 
Q1: HERC1, A: A-RAF, B: B-RAF, and C: C-RAF) were analyzed by immunoblotting with antibodies against the indicated proteins. (B, C) 
U2OS cells were transfected with NT or HERC1 siRNAs. Seventy-two hours later, cells were treated with 10 μM Sorafenib or 10 μM 
LY3009120 for 2 hours. Lysates were analyzed as in (A). Data are representative of at least three independent experiments.
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The ubiquitin ligase HERC1 regulates C-RAF 
ubiquitylation
Previous reports have demonstrated ubiquitylation 
and degradation of C-RAF via the proteasome [37–40]. 
A polyubiquitin chain linked through lysine 48 is the 
principal signal for targeting substrates to the proteasome. 
To check whether C-RAF can be polyubiquitylated, HEK-
293T cells were transfected with plasmids expressing 
C-RAF-GFP and His-Ubiquitin, or with the negative 
control pcDNA3. Twenty-four hours later, lysates from 
these cells containing His-Ubiquitin-tagged proteins were 
pulled-down using Ni-NTA agarose, a nickel-charged 
affinity resin for purifying recombinant proteins carrying 
a His tag. Inputs and purified proteins were analyzed by 
PAGE/SDS and immunoblotted with specific antibodies 
(Figure 10A). A characteristic polyubiquitylation smear 
was detected with the anti-C-RAF antibody (Figure 10A, 
lane 2). To show that the polyubiquitin chain was linked 
through lysine 48, a plasmid expressing His-Ubiquitin with 
lysine 48 mutated to arginine (K48R) was also transfected 
and processed as above. In these conditions, C-RAF 
polyubiquitylation was not observed (Figure 10A, lane 3). 
We have also analyzed C-RAF polyubiquitylation in the 
absence and presence of the proteasome inhibitor MG132 
using the anti-ubiquitylated proteins (FK2) antibody. GFP 
pull-down of HEK-293T cells transfected with GFP or 
C-RAF-GFP showed an increase in polyubiquitylated 
C-RAF in the presence of MG132 (Figure 10B, lane 8 
compared with lane 6).
Knowing that HERC1 is a member of the HECT 
superfamily of E3 ubiquitin ligases, that HERC1 
knockdown increases the C-RAF level, and that C-RAF is 
polyubiquitylated through lysine 48, we wondered whether 
HERC1 could be regulating C-RAF ubiquitylation. To 
test this, HEK-293T cells were initially transfected with 
HERC1 or non-targeting siRNAs. Twenty-four hours 
later, cells were transfected with plasmids expressing His-
Ubiquitin and C-RAF-GFP, or GFP as a negative control. 
Forty-eight hours later, lysates from the cells containing 
His-Ubiquitin-tagged proteins were pulled-down with 
Ni-NTA resin. Inputs and purified proteins were analyzed 
by PAGE/SDS and immunoblotting (Figure 10C). We 
observed that the polyubiquitylation smear detected 
with anti-C-RAF antibody was decreased after HERC1 
knockdown. These data show that HERC1 regulates 
C-RAF ubiquitylation. To analyze whether C-RAF can be 
the ubiquitylation substrate of HERC1, we performed an 
in vitro ubiquitylation assay. When purified His-HERC1 
and C-RAF-GFP proteins were incubated in a buffer that 
contained ATP, ubiquitin, and E1 and E2 enzymes, C-RAF 
polyubiquitylation was observed (Figure 10D).
Figure 5: Regulation of cell proliferation by HERC1 is RAF dependent. HeLa cells were transfected with the indicated siRNA 
(NT: non-targeting, Q1: HERC1, A: A-RAF, B: B-RAF, and C: C-RAF). (A) Colony formation assay was performed as indicated in 
“Materials and Methods” and cells were stained with crystal violet. (B) Crystal violet absorbance was quantified (n = 3). Data are expressed 
as mean ± S.E.M. Statistical analysis was carried out as described under “Materials and Methods”. *, p< 0.05.
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DISCUSSION
HERC1 is a giant protein that contains in its primary 
structure a HECT domain, which is characteristic of a 
large family of E3 ubiquitin ligases [9]. The present study 
reveals an important role of HERC1 in cell homeostasis. 
Our results show how dysregulation of HERC1 function 
by its interference RNA increases cell proliferation. These 
data are consistent with previous studies that would 
suggest an association between HERC1 mutations and 
cancer [25, 26]. We demonstrate how HERC1 knockdown 
regulates cell proliferation by means of activation of 
ERK signaling through a mechanism dependent on RAF 
activity. We show that HERC1 interacts with RAF proteins 
and specifically modulates C-RAF stability, regulating its 
polyubiquitylation. We conclude that the E3 ubiquitin 
Figure 6: The increase of C-RAF activates ERK signaling. (A) Cells were transfected with NT or HERC1 siRNAs. Lysates were 
analyzed by immunoblotting with antibodies against the indicated proteins. CHC protein was analyzed as a loading control. 293T: HEK-
293T. (B) U2OS cells were transfected with the indicated plasmids. Forty-eight hours later, lysates were analyzed as in (A). (C) Lysates 
from U2OS cells transfected with NT or HERC1 siRNAs were incubated on ice with glutaraldehyde at the indicated concentrations for 30 
min, and C-RAF oligomerization was analyzed by immunoblotting with anti-C-RAF antibody as indicated under “Materials and Methods”. 
Data are representative of at least three independent experiments.
Oncotarget31540www.oncotarget.com
ligase HERC1 controls cellular proliferation through 
activation of ERK signaling by regulating C-RAF protein 
levels via ubiquitylation.
These data implicate for the first time the E3 
ubiquitin ligase HERC1 in the model of regulating 
C-RAF activity. It has been reported that C-RAF 
autophosphorylation at Serine 621 stabilizes C-RAF, 
inhibiting its degradation by the proteasome [40]. 
Interestingly, in the absence of Serine 621 
phosphorylation, C-RAF is degraded by the proteasome 
by mechanisms that involves an unknown E3 ubiquitin 
ligase [40–41]. Our results are compatible with the 
participation of HERC1 in this model, where C-RAF is 
marked with a polyubiquitylation signal for degradation 
Figure 7: HERC1 interacts with C-RAF. (A) Supernatants (input) of lysates from HEK-293T cells were immunoprecipitated (IP) 
using anti-HERC1 antibodies (I) and analyzed by immunoblotting with antibodies against the indicated proteins. Pre-immune serum (PI) 
was used as a negative control. (B) Similar experiments were performed in HEK-293T cells transfected with C-RAF-GFP, and (C) in HeLa 
cells and in rat liver. (D) HEK-293T cells were deprived of serum overnight and stimulated with 120 ng/ml EGF for 5 min. Lysates were 
treated as in (A). Data are representative of at least three independent experiments.
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by the proteasome. The level of C-RAF protein would 
be determined by an equilibrium between the activity of 
E3 ubiquitin ligase of HERC1 (degradation) and its own 
kinase activity (stability). In this model, and in accordance 
with our observations, HERC1 depletion would increase 
the amount of C-RAF and this would be enough to activate 
the ERK signaling pathway.
The RAF/MEK/ERK signaling pathway regulates 
fundamental cellular processes including growth, 
proliferation, differentiation, survival and migration 
[1]. The importance of this regulation is revealed when 
the pathway is altered. Aberrant regulation of this 
signaling pathway has long been associated with human 
cancers. For this reason, it has been the subject of 
Figure 8: Domains involved in the interaction between HERC1 and C-RAF proteins. Structure of HERC1 (A) and C-RAF (B) 
proteins. Relevant domains are indicated. GFP fusion proteins with the amino acid residues expressed are shown. Pull-down experiments 
were performed in HEK-293T cells transfected with GFP or GFP-HERC1 fusion constructs (A), or with myc-HERC1 (1-1413) and GFP 
or GFP-C-RAF fusion constructs (B). About 24-48 hours post-transfection, lysates from these cells were incubated with GFP-binding 
beads as indicated in “Materials and Methods”. Proteins retained in the resin were analyzed by immunoblotting with antibodies against the 
indicated proteins.
Oncotarget31542www.oncotarget.com
intense research and pharmaceutical scrutiny to identify 
target-based approaches for cancer treatment [3, 42]. 
Currently, inhibitors of RAF activity probably represent 
the most studied approach for blocking ERK signaling. 
For example, the inhibitor of RAF activity Sorafenib is 
used as a therapy in renal cell carcinoma, hepatocellular 
Figure 9: Colocalization of HERC1 and C-RAF proteins. (A) Specificity of the anti-HERC1 antibody. HEK-293T cells infected 
with lentivirus (shHERC1: shRNA of HERC1; pLKO: the lentivirus plasmid vector as negative control) were stained for HERC1 (red), 
F-actin (green) and nuclei (blue), and analyzed by confocal microscopy. (B) Confocal immunofluorescence analysis shows partial 
colocalization of endogenous HERC1 and C-RAF proteins. HEK-293T cells were stained for HERC1 (red), C-RAF (green) and nuclei 
(blue), and analyzed by confocal microscopy. Colocalization is observed in the merge panel. (C) HEK-293T cells transfected with C-RAF-
GFP and myc-HERC1 (1-1413) constructs were stained for myc (myc-HERC1) (red), GFP (C-RAF-GFP) (green) and nuclei (blue), and 
analyzed by confocal microscopy. Colocalization is observed in the merge panel. (D) Pearson’s correlation coefficient (POC) and the 
Manders’ overlap coefficient (MOC) are showed (56 cells were used for colocalization analysis of endogenous proteins (B) and 19 cells for 
analysis of transfected constructs (C)). Data are representative of three independent experiments.
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carcinoma, melanomas and multiple myeloma [3, 42–44]. 
This inhibitor led to a significant disruption of Serine 621 
phosphorylation and decreased stability of C-RAF [40]. 
The antitumor activity of the antibiotic Geldanamycin 
and its analogues is due to binding to and promoting 
HSP90 degradation; HSP90 functions as a chaperone 
that is required for the stability and function of C-RAF. 
Hence, it indirectly inhibits the function of C-RAF by 
promoting its proteasomal degradation [3]. A similar 
effect would be observed stimulating the ubiquitin-ligase 
Figure 10: HERC1 regulates C-RAF ubiquitylation. (A) HEK-293T cells were transfected with C-RAF-GFP and pcDNA3, His-
Ubiquitin or His-Ubiquitin-K48R constructs. Twenty-four hours later, supernatants (input) were analyzed by immunoblotting with specific 
antibodies and His-tagged proteins purified using a Ni-NTA-agarose resin as indicated in “Materials and Methods”. The C-RAF protein 
retained in the resin was analyzed by immunoblotting with a specific anti-C-RAF antibody. (B) HEK-293T cells transfected with GFP or 
C-RAF-GFP were incubated in the presence of the proteasome inhibitor MG132 (10 μM) for 6 hours. Control cells were incubated with 
dimethyl sulfoxide (DMSO). GFP pull-down was performed as indicated in “Materials and Methods”. Proteins retained in the resin were 
analyzed by immunoblotting with the indicated antibodies. (C) HEK-293T cells were transfected with NT or HERC1 siRNAs. Twenty-four 
hours later, cells were transfected with His-Ubiquitin and GFP or C-RAF-GFP. Forty-eight hours later, His-tagged ubiquitin were purified 
using a Ni-NTA-agarose resin. Inputs and pull-downs were analyzed as in (A). (D) Purified His-HERC1 and C-RAF-GFP proteins were 
incubated in a buffer containing ATP, ubiquitin, and E1 and E2 enzymes as indicated in “Materials and Methods”. The reaction products 
were analyzed by immunoblotting. Data are representative of three independent experiments.
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activity of HERC1, which would specifically promote the 
proteasomal degradation of C-RAF. In this context, it has 
been shown that C-RAF is essential for development of 
K-RAS oncogene-driven non-small cell lung carcinoma 
(NSCLC) [45]. The search and identification of 
pharmaceutical stimulators of HERC1 activity could have 
great therapeutic potential in a variety of tumor types, 
including NSCLC, which is driven by the RAS oncogene 
most frequently mutated in human cancer.
HERC1 was discovered more than 20 years ago 
[11]. During this time, several proteins such as ARF, 
Rab, Clathrin, M2-pyruvate kinase, TSC2 and BAK 
have been described to interact with HERC1 [9]. Now, 
we demonstrate that RAF proteins also form part of the 
HERC1 interactome. Although some of the above proteins 
may participate in processes regulated by HERC1, to our 
knowledge, C-RAF is the first substrate reported for the 
E3 ubiquitin ligase activity of HERC1. It is intriguing to 
observe that despite its interaction with all RAF isoforms, 
HERC1 specifically targets C-RAF for degradation. 
Interestingly, knockdown experiments (Figure 4A and 
Figure 5) and experiments with RAF inhibitors (Figure 
4B-C) show the involvement of all RAF isoforms in the 
regulation of ERK signaling and cell proliferation by 
HERC1.
In summary, we identify a new function for the E3 
ubiquitin ligase HERC1 as a regulator of ERK signaling. 
Our findings indicate that HERC1 interacts with RAF 
proteins and controls C-RAF stability through regulation 
of its polyubiquitylation. These data show the important 
role of HERC1 in cell homeostasis, contribute to clarify 
the activation model of C-RAF, and point out pathological 
consequences of HERC1 dysregulation.
MATERIALS AND METHODS
Reagents
Anti-p-ERK1/2 (Sigma-Aldrich); anti-HERC1 
(Bvg6 and 410) [46]; anti-Clathrin heavy chain and 
anti-C-RAF (BD Biosciences); anti-B-RAF (F-7) 
and anti-A-RAF(A-5) (Santa Cruz Biotechnology); 
anti-p44/42 MAPK (ERK1/2) and anti-His-Tag (27E8) 
(Cell Signaling); anti-GFP (Abcam); anti-α-Tubulin 
(Calbiochem); anti-ubiquitinylated proteins (clone FK2) 
(Biomol); horseradish peroxidase-conjugated secondary 
antibodies, and Alexa-Fluor 488 and 555 conjugated 
secondary antibodies (Invitrogen); anti-chicken IgY-
peroxidases (Sigma-Aldrich) protein A-Sepharose and 
protein G-Sepharose (GE Healthcare); Phalloidin-Alexa 
647 (BioProbes); DAPI (Sigma-Aldrich); Immobilon-P 
PVDF transfer membrane (Millipore Corp.); GFP-TrapA 
(Chromotek); U0126 (Calbiochem); Sorafenib (Santa Cruz 
Biotech.); LY3009120 (Selleckchem); MG132 (Merck 
Millipore); Ni-NTA Agarose (Qiagen); Recombinant 
Human His6-Ubiquitin-activating Enzyme/UBE1 
(Boston Biochem); EGF (PeproTech); Ubiquitin (human- 
recombinant) (Enzo).
Plasmids and siRNAs
C-RAF-myc-His construct, C-RAF-GFP construct, 
His-Ubiquitin constructs (WT and K48R) and pT7-7-His-
UbcH5 constructs (a, b and c) were provided by Dr. A. 
Bajljuls/M. Halasz [47], Dr. T. Balla [48], Dr.T. Erazo 
[49] and Dr. K. Iwai [50], respectively. GFP-HERC1 
fusion constructs (1-412, 1-1334, 1-2958, 365-794, 754-
1334, and 3152-461), and myc-HERC1 (1-1413) were 
generated from human HERC1 cDNA [11] by digestion 
with appropriated restriction enzymes and subcloning 
in pEGFP or pCMV-Tag3 vectors, respectively. GFP-C-
RAF fusion constructs: cDNAs encoding residues 1–200, 
201-300 and 301-648 of human C-RAF were amplified 
by PCR using specific oligonucleotides. Amplified 
fragments were digested with Eco RI/Sma I restriction 
enzymes and subcloned into pEGFP-C2. Plasmids were 
sequenced. Baculovirus encoding human His-HERC1 
was previously reported [13]. MISSION shRNA clone of 
human HERC1 (TRCN0000235499) and the lentivirus 
plasmid vector pLKO.1-Puro were purchased from 
Sigma-Aldrich. The following siRNAs were used in 
this study: two siRNAs targeting the human sequence of 
HERC1 (Q1, CGGCAUGGAUGAACAAAUU and Q4, 
GGGCAGAACUUCGUUUAGA); non-targeting (NT) 
siRNA (NT, UAGCGACUAAACACAUCAA); A-RAF 
siRNA (AACAACATCTTCCTACATGAG); B-RAF 
siRNA (AAAGAATTGGATCTGGAT CAT); C-RAF 
siRNA (UAGUUCAGCAGUUUGGCUATT) were 
purchased from GenePharma.
Cell culture and transfections
HeLa, HEK-293T, U2OS, H1299 and A549 cells 
were cultured at 37°C in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Gibco) with 10% fetal bovine 
serum. Transfection of cells was carried out using 
calcium phosphate for siRNAs, and polyethylenimine 
(PEI) or Lipofectamine LTX (Invitrogen) for plasmids. 
The final concentration of siRNAs was 100 nM and 
the plasmid DNA amount was 2 μg (for lipofectamine 
LTX) or 8 μg (for PEI). Cells transfected with plasmids 
were analyzed 24-48 hours later. Cells transfected 
with plasmids and siRNAs or only with siRNAs were 
recovered at 72 hours post-transfection. Specific 
inhibitors were used at a final concentration of 10 
μM (U0126 for 1 hour, Sorafenib and LY3009120 
for 2 hours, and MG132 for 6 hours). Preparation of 
lentiviral transduction particles and their infection were 




Cells or tissues were lysed with NP40 buffer (50 
mM Tris-HCl, pH 7.5, 150 mM NaCl, 50 mM NaF, 0.5% 
NP40) containing protease and phosphatase inhibitors 
(50 mM β-glycerophosphate, 1 mM sodium vanadate, 1 
mM phenylmethylsulfonyl fluoride, 5 μg/ml leupeptin, 
5 μg/ml aprotinin, 1 μg/ml pepstatin A, 100 μg/ml 
benzamidine and 1μM E-64). Lysates were maintained 
on ice under agitation for 20 min, and then centrifuged at 
13,000 g at 4°C for 10 min. Supernatants were collected 
to be analyzed using the Tris-Acetate PAGE system [51]. 
Band intensities were detected using a gel documentation 
system (LAS-3000, Fujifilm) and quantified with ImageJ 
software. Protein levels were normalized and expressed as 
a percentage of controls.
Immunoprecipitation and pull-downs
For immunoprecipitation (IP), supernatants (input) 
were incubated with pre-immune serum (PI) or with anti-
HERC1 polyclonal antibody (Bvg6) for 2 hours at 4ºC 
with gentle rotation and immunoprecipitated with protein 
A-Sepharose for 1 hour at 4ºC. Beads were pelleted by 
centrifugation at 2,500 g, washed four times with NP40 
buffer, and analyzed by electrophoresis and immunoblot as 
it was indicated above. For GFP pull-downs, supernatants 
were incubated with 3μL of GFP-TrapA for 2 hours at 
4°C. Pellets were washed four times with NP40 buffer 
and analyzed by electrophoresis and immunoblotting as 
indicated above.
Clonogenic assay
For clonogenic assays, U2OS and HeLa cells were 
transfected with the indicated siRNAs and 24 hour post 
transfection cells were trypsinized and 1000 cells were 
reseeded in a DMEM with 5% new born calf serum and 
grown until cells formed sufficiently large colonies (12-15 
days). The colonies were stained with crystal violet and 
quantified by absorbance at 550 nm.
Confocal microscopy
HEK-293T cells were grown on glass coverslips 
and fixed with 4% paraformaldehyde for 20 min at room 
temperature. Cells were blocked and permeabilized 
with 0.5% bovine serum albumin and 0.05% Saponin in 
PBS for 20 minutes. The primary antibodies, anti-myc 
(1:100), anti-C-RAF (1:100) and anti-HERC1 (410; 
1:100), were incubated at 37°C for 1 hour. After washing, 
secondary antibodies (1:500) were incubated at 37ºC 
for 45 minutes. F-actin was detected incubating for 20 
minutes at room temperature with Phalloidin-Alexa 647 
(100 ng/ml). Nuclei were stained with DAPI (1 μg/ml). 
Images from optical sections (thickness: 0,31 μm) were 
acquired using a Carl Zeiss LSM 880 spectral confocal 
laser scanning microscope (Carl Zeiss Microscopy GmbH, 
Jena, Germany) using a 63x oil immersion objective 
(1.4 numerical aperture) and image resolution of 1024 
X 1024 pixels. Pearson’s correlation coefficient (POC) 
and Manders’ overlap coefficient (MOC) were calculated 
using ImageJ software.
Protein cross-linking assay
Cells were transfected with the indicated siRNAs 
and lysed in NP40 buffer 72 hours after transfection. After 
lysis, cells were centrifuged, and the supernatant was 
recovered. Glutaraldehyde was added to the supernatant 
at the indicated concentrations and incubated on ice for 
30 min, as described previously. The reaction was stopped 
with sample buffer (1x final concentration) and samples 
were analyzed by immunoblotting analysis as indicated 
above.
Ubiquitylation in vivo and in vitro assay
For the in vivo ubiquitylation assay, we followed 
the method described by Erazo et al. [49]. In brief, 
HEK-293T cells were transfected with the indicated 
siRNAs and plasmids for 72 hours and harvested by 
denaturing buffer (6 M guanidinium-HCl, 10 mM 
Tris, 100 mM Na2HPO4-NaH2PO4 buffer, pH 8). Cells 
extracts were then incubated with the nickel beads 
(Ni2+-NTA) for 2 hours at 4°C with rotation. Beads 
were successively washed as follows: twice with 1 
ml of buffer 1 plus 10 mM 2-mercaptoethanol; three 
times with 1 ml of buffer 2 (8 M urea, 10 mM Tris, 10 
mM 2-mercaptoethanol, 100 mM Na2HPO4- NaH2PO4 
buffer, pH 8); twice with 1 ml of buffer 3 (8 M urea, 
10 mM Tris, 100 mM Na2HPO4-NaH2PO4 buffer, pH 
6.3) containing 0.2% Triton X-100; once with 1 ml 
of buffer 3 containing 0.1% Triton X-100 and 0.5 M 
NaCl; and three times with 1 ml of buffer 3. Finally, 
proteins were eluted by incubating the beads with 200 
mM imidazole in 5% SDS, 0.15 M Tris-HCl, pH 6.7, 
30% (vol/vol) glycerol, 0.72 M 2-mercaptoethanol for 
1 hour at 37°C with mixing. The samples were analyzed 
by immunoblotting analysis as indicated above.
For the in vitro ubiquitylation assay, His-HERC1 
protein was purified from Sf9 cells infected with HERC1 
baculovirus using Ni-NTA resin [13]. C-RAF-GFP was 
purified from HEK-293T using GFP-TrapA beads. E2 
enzymes were purified from bacteria transformed with 
plasmids expressing His-UbcH5a, His-UbcH5b and 
His-UbcH5c proteins [13, 50]. Commercial purified E1 
enzyme and ubiquitin were also used. Purified HERC1 and 
C-RAF-GFP were incubated for 2 hours at 30°C in 50μL 
reaction buffer containing 0.5μg E1, 2μM ubiquitin, 1μg 
His-UbcH5a, 1μg His-UbcH5b, 1μg His-UbcH5c, 2.5mM 
ATP, 5mM MgCl2, 5mM KCl, 1mM DTT and 20mM 
HEPES (pH7.3). The reaction products were analyzed by 
immunoblotting analysis as indicated above.
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Statistical analysis
Data are presented as mean ± SEM. Statistical 
significance was determined by Student’s t test or One-
way Anova using GraphPad Prism 5 software. p values 
under 0.05 were considered statistically significant.
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